Form 4/A for CADL Candel Therapeutics, Inc.

Accepted 2023-02-17 00:00:00 ET · period of report 2022-12-08 · accession 0000899243-23-005523 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MAI	2023-02-17	2022-12-08+	CADL	Martell Christopher	Dir	P - Purchase	$1.89	+27.0K	128.1K	+27%	+$51.1K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-12-09	P	A	23,950	$1.92	152,000	I By GTAM1 2012 LLC	—	—	(F2) The price in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.88 to $1.98. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. (F3) Shares held by GTAM1 2012 LLC, which is wholly owned by a trust for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.
2	Common	Common Stock	2022-12-08	P	A	3,050	$1.68	128,050	I By GTAM1 2012 LLC	—	—	(F1) The price in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.55 to $1.80. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. (F3) Shares held by GTAM1 2012 LLC, which is wholly owned by a trust for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.